Blood-brain barrier permeability during the development of experimental bacterial meningitis in the rat

Experimental Neurology

Volumn 145, Issue 1, 1997, Pages 253-257

  Kim, Kwang Sik ^a   Wass, Carol A ^a   Cross, Alan S ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID FLOW; DISEASE TRANSMISSION; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031149928     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6458     Document Type: Article

References (26)

1. Bortolussi R., Ferrieri P., Wannamaker L. W. Dynamics ofEscherichia coli. Infect. Immun. 22:1978;480-485.
2. Brightman M. W. The anatomic basis of the blood-brain barrier. Implications of the Blood-Brain Barrier and Its Manipulation, Vol. 1, Basic Science Aspects. 1989;Plenum, New York. p. 53-83.
3. Brightman M. W., Reese T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40:1969;648-677.
4. Cross A. S., Sadoff J. C., Kelly N. M., Burton A., Gemski P. Pre-treatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin-1 alpha protects mice from lethal bacterial infection. J. Exp. Med. 169:1989;2021-2027.
5. Ferrieri P., Burke B., Nelson J. Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes. Infect. Immun. 27:1980;1023-1032.
6. Johanson C. E. Potential for pharmacologic manipulation of the blood-cerebrospinal fluid barrier. Neuwelt E. A. Implications of the Blood-Brain Barrier and Its Manipulation, Vol. 1, Basic Science Aspects. 1989;223-260 Plenum, New York.
7. Kim K. S. Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin and ampicillin-chloramphenicol in treatment of experimentalE. coli. Antimicrob. Agents Chemother. 28:1985;433-436.
8. Kim K. S. Effect of antimicrobial therapy for experimental infections due to group B streptococcus on mortality and clearance of bacteria. J. Infect. Dis. 155:1987;1233-1241.
9. Kim K. S. Efficacy of human immunoglobulin and penicillin G in treatment of experimental group B streptococcal infection. Pediatr. Res. 21:1987;289-292.
10. Kim K. S. Therapeutic efficacy of chloramphenicol, trimethoprim/sulfa methoxazole, cefmenoxime and ceftriaxone inexperimental bacteremia and meningitis due to an ampicillin-resistant strain ofHaemophilus influenzae. J. Antimicrob. Chemother. 22:1988;697-706.
11. Kim K. S., Bayer A. S. Efficacy of BMY-28142 in experimental bacteremia and meningitis due toEscherichia coli. Antimicrob. Agents Chemother. 28:1985;51-54.
12. Kim K. S., Cross A. S., Zollinger W., Sadoff J. Prevention and therapy of experimentalE. coli. Infect. Immun. 50:1985;735-737.
13. Kim K. S., Dunn K., McGeary S. A., Stiehm E. R. Efficacy of orally administered immune serum globulin against type III group B streptococcal colonization and systemic disease in an infant rat model. Pediatr. Res. 18:1984;1329-1331.
14. Kim K. S., Itabashi A., Gemski P., Sadoff J., Warren R. L., Cross A. S. The K1 capsule is the critical determinant in the development ofEscherichia coli. J. Clin. Invest. 90:1992;897-905.
15. Kim K. S., Wass C. A., Cross A. S., Opal S. M. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res. 11:1992;293-298.
16. Klein J. O., Feigin R. D., McCracken G. H. Jr. Report on the task force on diagnosis and management of meningitis. Pediatrics. 78:1986;959-982.
17. Mustafa M. M., Ramilo O., Mertsola J., Risser R. C., Beutler B., Hansen E. J., McCracken G. H. Jr. Modulation of inflammation and cachectic activity in relation to treatment of experimentalHaemophilus influenzae. J. Infect. Dis. 160:1989;818-825.
18. Mustafa M. M., Ramilo O., Olsen K. D., Franklin P. S., Hansen E. J., Beutler B., McCracken G. H. Jr. Tumor necrosis factor in mediating experimentalHaemophilus influenzae. J. Clin. Invest. 84:1989;1253-1259.
19. Quagliarello V. J., Long W. J., Scheld M. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat. J. Clin. Invest. 77:1986;1084-1095.
20. Reese T. S., Karnovsky M. J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34:1967;207-217.
21. Sande M. A., Scheld W. M., McCracken G. H. Jr. Summary of a workshop: Pathophysiology of bacterial meningitis - Implications for new management strategies. Pediatr. Infect. Dis. J. 6:1987;167-1171.
22. Siegel J. D., McCracken G. H. Sepsis neonatorum. N. Engl. J. Med. 304:1981;642-647.
23. Smith A. L., Smith D. H., Averill D. R. Jr., Marino J., Moxon E. R. Production ofHaemophilus influenzae. Infect. Immun. 8:1973;278-290.
24. Smith A. L., Roberts M. C., Haas J. E., Stull T. L., Mendelman P. M. Mechanisms ofHaemophilus influenzae. Sande M. A., Smith A. L., Root R. K. Contemporary Issues in Infectious Diseases, Vol. 3, Bacterial Meningitis. 1985;11-21 Churchill Livingstone, New York.
25. Smith Q. R. Quantitation of blood-brain barrier permeability. Neuwelt E. A. Implications of the Blood-Brain Barrier and Its Manipulation, Vol. 1, Basic Science Aspects. 1989;85-118 Plenum, New York.
26. Snedecor G. W., Cochran W. G. Statistical Methods. 1989;Iowa State University, Ames.